A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2015 by Academic Myeloma Consortium
Criterium, Inc.
Onyx Pharmaceuticals
Celgene Corporation
Information provided by (Responsible Party):
Academic Myeloma Consortium
ClinicalTrials.gov Identifier:
First received: October 19, 2011
Last updated: June 22, 2015
Last verified: June 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2020
  Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)